Sammibi (mtck-7)

DESCRIPTION

Active Substance: Each vial contains 1 mg [tetrakis (1 isocyanide- 2-methoxy-2 methylpropyl) copper (I)] tetrafluoroborate.

Sammibi is for diagnostic use only.

After radiolabelling with sodium pertechnetate (99m-Tc) solution, the solution obtained is indicated for:

• Myocardial perfusion scintigraphy for the detection and localisation of coronary artery disease (angina pectoris and myocardial infarction)

• Assessment of global ventricular function. First- pass technique for determination of ejection fraction and/or ECG-triggered, gated SPECT for evaluation of left ventricular ejection fraction, volumes and regional wall motion

• Scintimammography for the detection of suspected breast cancer when mammography is equivocal, inadequate or indeterminate

• Localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent disease in both primary and secondary hyperparathyroidism, and in patients with primary hyperparathyroidism scheduled to undergo initial surgery of the parathyroid glands

For more specific information regarding Sammibi, such as the dosage and pharmacological properties, please refer to the SmPC in your region:

Sweden (46063) -  SmPC in SE   

Finland (29687) - SmPC in FI  

Norway (11-8271) - SmPC in NO